Saw the interview last night. Obviously Kempler puts a positive...

Saw the interview last night. Obviously Kempler puts a positive spin where possible, which is to be expected. He indicated that cognition benefits had been proven in an earlier trial (the 2008 Euro trial over 12 weeks with 78 patients). He didn't really answer why , even though they were secondary end points, in the most recent Imagine trial (42 patients over 12 months) didn't show cognition benefits. Can only hope that the same mystery that impacted on failure to meet the primary end point (where placebo results also showed improvement) applies to cognition and functional efficiency. Its been almost 6 years between the Euro and Imagine trial results and unless the current extension trial can pull a rabbit out of the hat we may need to wait a while to find out which of the two trials was the abnormality.